

| Dosage | Package | Price per Dose | Price | |
|---|---|---|---|---|
| 200mg | 270 pills | C$1.61 | C$510.81 C$434.19 Best Price | |
| 200mg | 180 pills | C$1.76 | C$373.98 C$317.88 | |
| 200mg | 120 pills | C$1.94 | C$273.64 C$232.59 | |
| 200mg | 90 pills | C$2.05 | C$216.62 C$184.13 | |
| 200mg | 60 pills | C$2.23 | C$157.33 C$133.73 | |
| 200mg | 30 pills | C$2.33 | C$82.08 C$69.76 | |
| 200mg | 20 pills | C$2.42 | C$56.99 C$48.44 | |
| 200mg | 10 pills | C$2.71 | C$31.90 C$27.12 | |
| 400mg | 270 pills | C$2.95 | C$934.98 C$794.74 | |
| 400mg | 180 pills | C$3.10 | C$656.76 C$558.25 | |
| 400mg | 120 pills | C$3.20 | C$451.52 C$383.79 | |
| 400mg | 90 pills | C$3.30 | C$348.89 C$296.56 | |
| 400mg | 60 pills | C$3.39 | C$239.43 C$203.52 | |
| 400mg | 30 pills | C$3.49 | C$123.12 C$104.66 | |
| 400mg | 20 pills | C$3.59 | C$84.36 C$71.70 | |
| 400mg | 10 pills | C$3.68 | C$43.31 C$36.81 | |
| 550mg | 270 pills | C$3.49 | C$1,108.30 C$942.06 Popular | |
| 550mg | 180 pills | C$3.59 | C$759.38 C$645.48 | |
| 550mg | 120 pills | C$3.88 | C$547.30 C$465.20 | |
| 550mg | 90 pills | C$4.07 | C$430.99 C$366.34 | |
| 550mg | 60 pills | C$4.17 | C$294.16 C$250.04 | |
| 550mg | 30 pills | C$4.32 | C$152.77 C$129.86 | |
| 550mg | 20 pills | C$4.56 | C$107.16 C$91.09 | |
| 550mg | 10 pills | C$4.85 | C$56.99 C$48.44 |
Rifaximin is a gut-targeted rifamycin antibiotic that inhibits bacterial RNA synthesis, remaining largely in the gastrointestinal tract with minimal systemic absorption. It is used to treat traveler’s diarrhea caused by noninvasive E. coli and to prevent episodes of hepatic encephalopathy in people with liver disease; it is also approved for irritable bowel syndrome with diarrhea (IBS-D) in adults.
Rifaximin is an antibiotic in the rifamycin class. It acts locally in the gut, targeting gut bacteria by inhibiting RNA polymerase and blocking transcription. Because most of the drug stays in the intestines, systemic side effects are less common.
Traveler’s diarrhea caused by noninvasive E. coli.
Recurrent hepatic encephalopathy in adults with cirrhosis.
Irritable bowel syndrome with diarrhea (IBS-D) in adults.
Take rifaximin exactly as prescribed. Do not alter the dose on your own. The drug can be taken with or without food.
Common regimens vary by condition. For traveler’s diarrhea, the usual course is 200 mg three times daily for 3 days. For IBS-D, 550 mg three times daily for 14 days. For hepatic encephalopathy prevention, 550 mg twice daily is typical, sometimes long-term under medical supervision. Your doctor will specify the right plan for you.
Swallow tablets whole with water. Do not crush, chew, or break them unless your healthcare provider tells you to. If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular schedule. Do not double up doses to catch up.
Storage should be at room temperature, away from moisture and heat. Keep the medication in its original container and tightly closed. Keep it out of reach of children. Do not use after the expiration date.
Most people tolerate rifaximin well. Common side effects include headache, nausea, abdominal pain, flatulence, and dizziness. Some may have heartburn or changes in bowel movements. Serious reactions are rare but can include severe allergic responses. Seek care if you notice swelling of the lips or tongue, trouble breathing, severe rash, or persistent signs of infection.
Contact a healthcare professional if you have signs of dehydration from diarrhea, or if symptoms worsen or persist beyond your prescribed course. If you have liver disease, discuss ongoing rifaximin use with your doctor. Tell your clinician about all medicines you take, as rifaximin can interact with other drugs. Seek immediate care for symptoms of a serious reaction or for pregnancy or breastfeeding questions.
14–21 days. Free from C$276.92 .
5–9 days. C$41.54
−10% when paying with cryptocurrency.
−10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
